Literature DB >> 25596457

Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.

Elodie Beaumont1, Philippe Roingeard2.   

Abstract

The development of an effective, affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. The recently described chimeric HBV-HCV subviral envelope particles could potentially be used for this purpose, as they could be produced by industrial procedures adapted from those established for the hepatitis B virus (HBV) vaccine. We show here, in an animal model, that pre-existing immunity acquired through HBV vaccination does not influence the immunogenicity of the HCV E2 protein presented by these chimeric particles. Thus, these chimeric HBV-HCV subviral envelope particles could potentially be used as a booster in individuals previously vaccinated against HBV, to induce protective immunity to HCV.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immune response; Liver diseases; Preventive vaccination; Subviral envelope particles; Viral hepatitis

Mesh：

Substances：

Year:  2015        PMID： 25596457      PMCID： PMC5666088          DOI： 10.1016/j.vaccine.2015.01.007

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Bioengineering virus-like particles as vaccines.

Authors:  Linda H L Lua; Natalie K Connors; Frank Sainsbury; Yap P Chuan; Nani Wibowo; Anton P J Middelberg
Journal:  Biotechnol Bioeng       Date:  2013-12-17       Impact factor: 4.530

Review 2.  Hepatitis B virus infection.

Authors:  Christian Trépo; Henry L Y Chan; Anna Lok
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

3.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.

Authors:  Anil G Suryaprasad; Jianglan Z White; Fujie Xu; Beth-Ann Eichler; Janet Hamilton; Ami Patel; Shadia Bel Hamdounia; Daniel R Church; Kerri Barton; Chardé Fisher; Kathryn Macomber; Marisa Stanley; Sheila M Guilfoyle; Kristin Sweet; Stephen Liu; Kashif Iqbal; Rania Tohme; Umid Sharapov; Benjamin A Kupronis; John W Ward; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2014-08-11       Impact factor: 9.079

Review 4.  Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

Authors:  Troels K H Scheel; Charles M Rice
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

5.  Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.

Authors:  Elodie Beaumont; Romuald Patient; Christophe Hourioux; Isabelle Dimier-Poisson; Philippe Roingeard
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

Review 6.  Treatment as prevention and cure towards global eradication of hepatitis C virus.

Authors:  Liesl M Hagan; Paul Root Wolpe; Raymond F Schinazi
Journal:  Trends Microbiol       Date:  2013-11-14       Impact factor: 17.079

7.  Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.

Authors:  Thijis van de Laar; Oliver Pybus; Sylvia Bruisten; David Brown; Mark Nelson; Sanjay Bhagani; Martin Vogel; Alex Baumgarten; Marie-Laure Chaix; Martin Fisher; Hannelore Gotz; Gail V Matthews; Stefan Neifer; Peter White; William Rawlinson; Stanislav Pol; Jurgen Rockstroh; Roel Coutinho; Greg J Dore; Geoffrey M Dusheiko; M Danta
Journal:  Gastroenterology       Date:  2009-05       Impact factor: 22.682

Review 8.  Prospects for prophylactic hepatitis C vaccines based on virus-like particles.

Authors:  Elodie Beaumont; Philippe Roingeard
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

9.  Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine.

Authors:  Hans J Netter; Wai-Ping Woo; Robert Tindle; Roderick I Macfarlan; Eric J Gowans
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

10.  A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.

Authors:  Bertrand Lell; Selidji Agnandji; Isabelle von Glasenapp; Sonja Haertle; Sunny Oyakhiromen; Saadou Issifou; Johan Vekemans; Amanda Leach; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Terrell Carter; Tonya Villafana; W Ripley Ballou; Joe Cohen; Peter G Kremsner
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240
View more
  10 in total

Review 1.  Status of hepatitis C virus vaccination: Recent update.

Authors:  Kouka Saadeldin Abdelwahab; Zeinab Nabil Ahmed Said
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 2.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

3.  Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties.

Authors:  Elodie Beaumont; Emmanuelle Roch; Lucie Chopin; Philippe Roingeard
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

Review 4.  Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.

Authors:  Makutiro Ghislain Masavuli; Danushka K Wijesundara; Joseph Torresi; Eric J Gowans; Branka Grubor-Bauk
Journal:  Front Microbiol       Date:  2017-12-05       Impact factor: 5.640

Review 5.  The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.

Authors:  Joseph Torresi
Journal:  Front Microbiol       Date:  2017-11-07       Impact factor: 5.640

6.  SnoopLigase peptide-peptide conjugation enables modular vaccine assembly.

Authors:  Anne-Marie C Andersson; Can M Buldun; David J Pattinson; Simon J Draper; Mark Howarth
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

7.  Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.

Authors:  Elsa Gomez-Escobar; Julien Burlaud-Gaillard; Clara Visdeloup; Adeline Ribeiro E Silva; Pauline Coutant; Philippe Roingeard; Elodie Beaumont
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.996

8.  Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.

Authors:  Anna Czarnota; Jolanta Tyborowska; Grażyna Peszyńska-Sularz; Beata Gromadzka; Krystyna Bieńkowska-Szewczyk; Katarzyna Grzyb
Journal:  Microb Cell Fact       Date:  2016-04-13       Impact factor: 5.328

9.  Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response.

Authors:  Sami Akhras; Masako Toda; Klaus Boller; Kiyoshi Himmelsbach; Fabian Elgner; Marlene Biehl; Stephan Scheurer; Meike Gratz; Stefan Vieths; Eberhard Hildt
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

Review 10.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.